Back to search
FDAFDA · Food and drugs·Recall number D-0834-2020

Ethacrynate Sodium for Injection, USP, 50mg/vial, Single Dose Vial, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 68382-246-01.

Published February 19, 2020 · Recall initiated: January 31, 2020

Summary

FDA records drug Class II recall D-0834-2020, published February 19, 2020 and initiated January 31, 2020. Recalling firm: Zydus Pharmaceuticals USA Inc; Status: Terminated; Reported quantity: 2207 Vials; Lot: Lot #s: M804062, Exp. 01/2020; M804063, M804064, Exp. 02/2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Zydus Pharmaceuticals USA Inc
Distributor
Nationwide in the U.S.
Lot
Lot #s: M804062, Exp. 01/2020; M804063, M804064, Exp. 02/2020
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ethacrynate Sodium for Injection, USP, 50mg/vial, Single Dose Vial, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 68382-246-01. recalled?

Yes. FDA published recall D-0834-2020 on February 19, 2020. Reported hazard: cGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter